ZA201304381B - Novel-19-nor-steroid and their use for treating progesterone-dependent conditions - Google Patents

Novel-19-nor-steroid and their use for treating progesterone-dependent conditions

Info

Publication number
ZA201304381B
ZA201304381B ZA2013/04381A ZA201304381A ZA201304381B ZA 201304381 B ZA201304381 B ZA 201304381B ZA 2013/04381 A ZA2013/04381 A ZA 2013/04381A ZA 201304381 A ZA201304381 A ZA 201304381A ZA 201304381 B ZA201304381 B ZA 201304381B
Authority
ZA
South Africa
Prior art keywords
steroid
novel
dependent conditions
treating progesterone
progesterone
Prior art date
Application number
ZA2013/04381A
Other languages
English (en)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/062068 external-priority patent/WO2011119194A1/en
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of ZA201304381B publication Critical patent/ZA201304381B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2013/04381A 2010-12-23 2013-06-13 Novel-19-nor-steroid and their use for treating progesterone-dependent conditions ZA201304381B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/062068 WO2011119194A1 (en) 2010-03-22 2010-12-23 Compositions and methods for non-toxic delivery of antiprogestins
PCT/US2011/050859 WO2012087389A1 (en) 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Publications (1)

Publication Number Publication Date
ZA201304381B true ZA201304381B (en) 2014-03-26

Family

ID=44681424

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04381A ZA201304381B (en) 2010-12-23 2013-06-13 Novel-19-nor-steroid and their use for treating progesterone-dependent conditions

Country Status (13)

Country Link
US (1) US20130274234A1 (enExample)
EP (1) EP2655394A1 (enExample)
JP (2) JP2014500316A (enExample)
KR (1) KR20130132955A (enExample)
CN (1) CN103403017A (enExample)
AU (1) AU2011345341B2 (enExample)
CA (1) CA2820877A1 (enExample)
MX (1) MX2013006732A (enExample)
NZ (1) NZ612295A (enExample)
SG (1) SG191207A1 (enExample)
UA (1) UA113283C2 (enExample)
WO (1) WO2012087389A1 (enExample)
ZA (1) ZA201304381B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704858PA (en) 2012-05-31 2017-07-28 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
EP2914268B1 (en) * 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
MX384159B (es) * 2014-05-05 2025-03-14 Repros Therapeutics Inc Formulaciones y métodos para el suministro vaginal de antiprogestinas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
DK1265911T3 (da) * 2000-03-17 2008-09-29 Us Gov Health & Human Serv 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
EP2078032B1 (en) * 2006-10-24 2017-08-02 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法

Also Published As

Publication number Publication date
AU2011345341B2 (en) 2016-10-20
US20130274234A1 (en) 2013-10-17
WO2012087389A1 (en) 2012-06-28
EP2655394A1 (en) 2013-10-30
AU2011345341A1 (en) 2013-07-04
NZ612295A (en) 2014-07-25
CA2820877A1 (en) 2012-06-28
SG191207A1 (en) 2013-07-31
JP2016180004A (ja) 2016-10-13
MX2013006732A (es) 2013-07-17
JP2014500316A (ja) 2014-01-09
CN103403017A (zh) 2013-11-20
UA113283C2 (xx) 2017-01-10
KR20130132955A (ko) 2013-12-05

Similar Documents

Publication Publication Date Title
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
IL221511A (en) Arilatriazolones associated with bis aryl and their use
EP2717931A4 (en) ASSOCIATIONS AND RELATED METHODS
GB201012175D0 (en) Procedure and mechanisms
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
ZA201208173B (en) Peptices and their use
GB201004172D0 (en) Skin treating device
GB201111705D0 (en) Compounds and their use
IL234829A0 (en) Methods and preparations for treating inflammation
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
ZA201303773B (en) Compounds and their use
ZA201309365B (en) Glioblastoma inhibiting compounds and their use
IL225483A0 (en) The compositions and methods for the treatment of neoplasia
EP2566483A4 (en) METHOD AND MEANS FOR IMPROVED WOUND HEALING
GB201111630D0 (en) Novel compounds and their use
SG10201510568WA (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
GB201114448D0 (en) Compounds and their use
IL238403A0 (en) Methods and preparations for the treatment of progesterone-dependent conditions
GB201013573D0 (en) Treatment
ZA201304381B (en) Novel-19-nor-steroid and their use for treating progesterone-dependent conditions
PL2606032T3 (pl) Kompozycja i sposoby terapii glejakaep
GB2500357B (en) Combination and composition for treating obesity
GB201014097D0 (en) Treatment